Beta Bionics (BBNX) investor relations material

Mint product and user experience

• Mint matches the size, weight, insulin capacity and wear time of the leading patch pump; reusable controller lasts two years without batteries or recharging, while disposable Mints are replaced every three days.

• Setup avoids phone interaction; Mint integrates with Libre and Dexcom and uses the iLet algorithm.

• In a 30-user side-by-side study, every participant rated Mint insertion as less painful than the incumbent patch pump.

• Starter kit includes the controller, user guide and 10 Mints; monthly refills may include 15 Mints for users needing more than 10.

Commercial plans and manufacturing

• Mint is the top operational priority; Irvine clean-room lines are producing devices in a crawl-walk-run scale-up, with further line evolution planned over the next six months.

• Production commitment is at least 1.5 million Mints in CY2027, with internal goals above that minimum; meaningful Mint revenue is expected in Q1 2027.

• Sales coverage expanded by 20 territories, roughly 30%, completing in late Q2 2026; reps continue selling iLet until Mint is commercially ready, with marketing to pivot at launch.

• Mint pharmacy-benefit access is targeted at 40% of U.S. patients at launch and 50% by the end of the first year; PBM agreements are won for iLet, and Mint contract amendments are in process.

• Management expects roughly two-thirds of 2027 Mint starts from new patients and one-third from iLet transitions; transitions from DME to pharmacy are also planned.

3D Intelligence and type 2 opportunity

• 3D Intelligence adds an optimized mode intended to reduce hypoglycemia while maintaining mean glucose and A1C, plus a conservative mode trading higher A1C for less time below 54 mg/dL.

• FDA review covers the two new modes, not the original algorithm; after late-stage simulator-validation questions, the submission was withdrawn and resubmitted.

• 3D Intelligence will be delivered as a firmware-over-the-air upgrade to users; management views mode choice as a significant sales opportunity, including for 2027.

• Type 2 trial enrollment is expected to complete by mid-2027; FDA agreed an observational trial and existing real-world data could support an indication, and the data can be marketed.